News | Radiation Therapy | July 20, 2021

ASTRO just issued the following statement in response to the Radiation Oncology Model update in yesterday's HOPPS proposed rule, which compounds significant and detrimental cuts to the cancer care specialty in the proposed 2022 MPFS

ASTRO just issued the following statement in response to the Radiation Oncology Model update in yesterday's HOPPS proposed rule, which compounds significant and detrimental cuts to the cancer care specialty in the proposed 2022 MPFS

Getty Images


July 20, 2021 — In response to consecutive weeks of proposed Medicare payment cuts to radiation oncology cancer care, Thomas J. Eichler, M.D., FASTRO, Chair of American Society for Radiation Oncology (ASTRO), issued the following statement:

“Access to radiation therapy for people with cancer is under attack. For two consecutive weeks, the Centers for Medicare and Medicaid Services (CMS) has singled out radiation oncology for payment cuts that put access to cancer care for Medicare beneficiaries in peril – at a time when cancer incidence rates are rising due to delayed screenings caused by the COVID-19 pandemic. By proposing to cut high-value radiation treatments by as much as 22% and proceeding with more than $160 million in reductions under the Radiation Oncology Model (RO Model), CMS is jeopardizing the ability of the nation’s radiation therapy professionals to continue to provide essential care for their patients now and in the future. Access to life-saving cancer treatments will suffer, and the viability of clinics already reeling from the pandemic will be at considerable risk if these proposals are finalized.

Given this urgent situation, the radiation oncology community calls upon President Joe Biden, a lifelong champion in the fight against cancer, to immediately intervene on the flawed RO model and proposed Medicare Physician Fee Schedule cuts. Likewise, we ask Congress to continue its longstanding support for radiation oncology care by taking action to blunt CMS’ draconian cuts and reform the RO model.

ASTRO remains committed to value-based care and to constructively engaging with CMS on reasonable ways to improve these policies. We are eager to help President Biden achieve his goal of ending cancer as we know it, and we are developing promising approaches to reduce health care disparities in cancer treatment. These difficult policy challenges require investments in our human and technological cancer care infrastructure that would be virtually impossible under the current proposals. Massive cuts such as those proposed by CMS will set us back, not move us forward, and ASTRO will vigorously oppose these threats to radiation oncology and our patients.”

For more information: www.astro.org


Related Content

Feature | Radiology Business | By Melinda Taschetta-Millane

One on One interviews with radiology trailblazers and historic FDA clearances made the top-read list for April. Take a ...

Time May 03, 2024
arrow
Feature | Radiation Dose Management | By Christine Book

Advances in the growing radiation dose management market are continually helping those who administer treatment to focus ...

Time May 03, 2024
arrow
News | Artificial Intelligence

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Radiation Therapy

April 18, 2024 — Accuray Incorporated announced that as part of its commitment to advancing patient care the company has ...

Time April 18, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Lung Imaging

April 17, 2024 — A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients ...

Time April 17, 2024
arrow
Subscribe Now